Nystatin A3 | 62997-67-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Nystatin A3
• 英文别名: (1S,3R,4R,7R,9R,11R,15S,16S,17R,18S,19E,21E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-17-[(4R,5R,6S)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-1,3,4,7,9,11,37-heptahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid
• CAS: 62997-67-5
• 化学式: C₅₃H₈₅NO₂₀
• 分子量: 1056.2
• InChiKey: IKYMLQOHQLVORI-PLAPNZKPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  74
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  358
• 氢给体数：
  13
• 氢受体数：
  21

文献信息

• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS<br/>[FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT D'INFECTIONS FONGIQUES
  申请人：CIDARA THERAPEUTICS INC

  公开号：WO2015164289A1

  公开（公告）日：2015-10-29

  Compositions and methods for the treatment of fungal infections including compounds containing a chemotaxis receptor ligand moiety and a polyene antifungal agent moiety are disclosed. In particular, compounds containing a polyene antifungal agent and a formyl peptide receptor ligand can be used in the treatment of fungal infections caused by a fungus of the genus Aspergillus or Candida.

  揭示了用于治疗真菌感染的化合物和方法，包括含有趋化受体配体基团和聚烯抗真菌剂基团的化合物。具体来说，含有聚烯抗真菌剂和甲酰肽受体配体的化合物可用于治疗由曲霉属或白念珠菌属真菌引起的真菌感染。
• [EN] UREA DERIVATIVES OF POLYENE MACROLIDE ANTIBIOTICS<br/>[FR] DÉRIVÉS D'URÉE D'ANTIBIOTIQUES MACROLIDES POLYÉNIQUES
  申请人：UNIV ILLINOIS

  公开号：WO2016040779A1

  公开（公告）日：2016-03-17

  Disclosed are urea derivatives of polyene macrolide antibiotics, other than amphotericin B, comprising a urea-containing substructure represented by wherein R represents hydrogen, alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, aminoalkyl, or -(CH2)n-COOH; and n is 1, 2, 3, 4, 5, or 6. Also disclosed are pharmaceutical compositions comprising the urea derivatives, methods of using the urea derivatives to inhibit growth of a yeast or fungus, and methods of treating a yeast or fungal infection. In various embodiments, the polyene macrolide antibiotic is selected from the group consisting of amphotericin A, arenomycin B, candicidin D, candidin, candidoin, CE-108, etruscomycin, eurocidin D, eurocidin E, FR-008-VI, HA-2-91, hamycin A, levorin AO, levorin A3, mycoheptin, natamycin (pimaricin), nystatin Al, nystatin A2, nystatin A3, partricin A, polyfungin B, rimocidin, tetramycin A, tetramycin B, tetrin A, tetrin B, tetrin C, trichomycin A, trichomycin B, vacidin A, YS-822A, 3874 HI, 3874 H2, 3874 H3, and 67-121-A.

  本发明涉及聚烯烃大环内酰胺类抗生素的脲衍生物，除了两性霉素B以外，包括一个含有脲基的亚结构，其表示为其中R表示氢、烷基、芳基、芳基烷基、杂芳基、杂芳基烷基、氨基烷基或-(CH2)n-COOH; n为1、2、3、4、5或6。本发明还涉及包含该脲衍生物的制药组合物，使用该脲衍生物抑制酵母或真菌生长的方法以及治疗酵母或真菌感染的方法。在各种实施方式中，聚烯烃大环内酰胺类抗生素选自以下组合：两性霉素A、阿诺霉素B、卡地西丁D、卡地西丁、卡地多因、CE-108、埃特鲁斯科霉素、欧洲杀菌素D、欧洲杀菌素E、FR-008-VI、HA-2-91、哈米霉素A、左旋霉素AO、左旋霉素A3、霉菌肝素、纳他霉素（皮马霉素）、制霉素Al、制霉素A2、制霉素A3、帕特里辛A、多菌灵B、利莫西汀、四菌素A、四菌素B、四菌素C、三联霉素A、三联霉素B、瓦西丁A、YS-822A、3874 HI、3874 H2、3874 H3和67-121-A。
• Methods for preventing and treating pneumocystis infections
  申请人：Cidara Therapeutics, Inc.

  公开号：US10369188B2

  公开（公告）日：2019-08-06

  The disclosure relates to methods of prophylactic and therapeutic treatments of a Pneumocystis infection (i.e., an infection caused by Pneumocystis jirovecii) in a subject by administering to the subject a compound of any of formulas (1)-(111) (e.g., a salt of Compound 1, or a neutral form thereof). The disclosure also relates to methods of inhibiting the replication of a Pneumocystis spp. The methods of the disclosure can be useful in immunocompromized subjects.

  本发明涉及通过向受试者施用式(1)-(111)中任何一种化合物（例如，化合物1的盐或其中性形式）来预防和治疗受试者肺孢子虫感染（即由肺孢子虫引起的感染）的方法。本公开还涉及抑制肺孢子虫属复制的方法。 本公开的方法可用于免疫功能低下的受试者。
• Antifungal compounds
  申请人：President and Fellow of Harvard College

  公开号：US10793590B2

  公开（公告）日：2020-10-06

  Compounds of formula (I) or formula (II), compositions and methods useful for treating and/or preventing a fungal infections are provided. wherein the substituents are as defined in the appended claims.

  本发明提供了式(I)或式(II)化合物、用于治疗和/或预防真菌感染的组合物和方法。 其中，取代基如所附权利要求中所定义。
• METHODS FOR PREVENTING AND TREATING PNEUMOCYSTIS INFECTIONS
  申请人：Cidara Therapeutics, Inc.

  公开号：EP3399995A1

  公开（公告）日：2018-11-14